Literature DB >> 29969002

National 10-year trends and outcomes of isolated and concomitant tricuspid valve surgery.

Abhijeet Dhoble1,2, Yelin Zhao3, Pimprapa Vejpongsa3,4, Catalin Loghin3,4, Richard W Smalling3,4, Anthony Estrera3,4, Tom C Nguyen3,4.   

Abstract

BACKGROUND: The data on the trends and comparative outcomes after isolated and concomitant tricuspid valve repair/replacement (TVR) is scarce.
METHODS: The International Classification of Diseases - 9th version was used to identify the patients who underwent TVR, using the National Inpatient Sample. Outcomes were evaluated using the analysis of variance and Chi-square test, and trends across the years were tested via Cochran-Armitage Test.
RESULTS: Of 6868 patients who underwent TVR between 2005-14, 1601 (23%) were isolated. Over the 10-years period, the number of total and isolated TVR has steadily increased (P<0.001). The proportion of patients undergoing repair has increased compared to replacement. Overall in-hospital mortality was 8.5% and 7.7% (p=0.28), permanent pacemaker requirement was 11.24% and 10.69% (P=0.53), blood transfusion rates were 32.6% and 37.9% (P<0.001), and the post-procedure length of stay (LOS) was 14.1±0.44 and 12.5±0.17 days (P<0.001) after isolated and concomitant TVR respectively. High (26.25%) number of patients were discharged to skilled facility. The operative mortality associated with TV repair was lower than with replacement (6.8% versus 11.15%, P<0.001), but the mortality trend over the 10-years has stayed relatively stable. Independent predictors of mortality were age >50 years, heart failure, cerebrovascular accident, end-stage renal disease, peripheral vascular disease, liver disease, and TV replacement.
CONCLUSIONS: Both isolated and concomitant TVR has increased over the last 10 years, however is associated with high mortality, complications, need for skilled facility placement, and longer LOS. The mortality after TV replacement was significantly higher than that after repair.

Entities:  

Mesh:

Year:  2018        PMID: 29969002     DOI: 10.23736/S0021-9509.18.10468-X

Source DB:  PubMed          Journal:  J Cardiovasc Surg (Torino)        ISSN: 0021-9509            Impact factor:   1.888


  4 in total

1.  Anisocytosis predicts postoperative renal replacement therapy in patients undergoing heart valve surgery.

Authors:  Piotr Duchnowski; Tomasz Hryniewiecki; Mariusz Kuśmierczyk; Piotr Szymański
Journal:  Cardiol J       Date:  2019-02-25       Impact factor: 2.737

2.  Tricuspid regurgitation: remembering 'the forgotten valve'.

Authors:  R J de Winter
Journal:  Neth Heart J       Date:  2022-08-03       Impact factor: 2.854

3.  Late Outcomes of Valve Repair Versus Replacement in Isolated and Concomitant Tricuspid Valve Surgery: A Nationwide Cohort Study.

Authors:  Wang-Kin Wong; Shao-Wei Chen; An-Hsun Chou; Hsiu-An Lee; Yu-Ting Cheng; Feng-Chun Tsai; Kuang-Tso Lee; Victor Chien-Chia Wu; Chun-Li Wang; Shang-Hung Chang; Pao-Hsien Chu
Journal:  J Am Heart Assoc       Date:  2020-04-17       Impact factor: 5.501

4.  Tricuspid valve repair in isolated tricuspid pathology: a 12-year single center experience.

Authors:  Alina Zubarevich; Marcin Szczechowicz; Andreas Brcic; Anja Osswald; Konstantinos Tsagakis; Daniel Wendt; Bastian Schmack; Michel Pompeu B O Sá; Jef Van den Eynde; Arjang Ruhparwar; Konstantin Zhigalov
Journal:  J Cardiothorac Surg       Date:  2020-11-16       Impact factor: 1.637

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.